Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

47.06 +0.73 (+1.58%)
Streaming Delayed Price Updated: 12:35 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 Next >
QIAGEN N.V. (NYSE:QGEN) Passes the Caviar Cruise Quality Investment Screen
QIAGEN NV exemplifies the Caviar Cruise investing method with strong sales growth, a 46% ROIC, and robust cash flow, signaling a high-quality business. 
Via Chartmill
Illumina's BioInsight Launch Sparks Optimism, Signals New Era for Genomic Data and AI
San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Look at Qiagen's Upcoming Earnings Report
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Qiagen Earnings Review: Q4 Summary
 
Via Benzinga
Qiagen: Q4 Earnings Insights
 
Via Benzinga
QIAGEN N.V. (NYSE:QGEN) - A Strong Technical Setup for Breakout Investors
QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance... 
Via Chartmill
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors. 
Via Chartmill
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors. 
Via Chartmill
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%. 
Via Benzinga
Earnings Scheduled For February 5, 2025
 
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Earnings Preview: Qiagen
 
Via Benzinga
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Via The Motley Fool
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches
QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements. 
Via Benzinga
QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024
QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition
U.S. stocks are looking to build on past week’s gains, with the mood remaining cautiously optimistic. The major index futures were modestly higher in early trading. 
Via Benzinga
Topics Economy
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc.... 
Via Benzinga
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing... 
Via Benzinga
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects
QIAGEN N.V. (NYSE: QGEN) disclosed its expansion plan in  
Via Benzinga
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.